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Introduction
Polycystic ovary syndrome PCOS affects approxi-
mately 5 to 10% of women of reproductive age. It is
the most common reason of anovulation in infertile
women. PCOS is accompanied by such conditions as
oligo- or anovulation, hipertestosteronism, lower cell
sensitivity to insulin, type II diabetes, hyperlipidemia
and obesity. Each of the above-mentioned conditions
is an approved risk factor proved to predispose
towards cancer. Women diagnosed with PCOS devel-
op higher level of testosterone, insulin, growth factors
such as IGF-1 (Insulin Growth Factor-1), which were
experimentally proved to have potential for direct
stimulatation of cancer cells proliferation. Direct stim-
ulation of cancer cells may result both from binding
testosterone to testosterone receptors on cell surface,
as well as peripheral androgen aromatization to estra-
diol followed by binding estradiol to estrogen recep-
tors, which may also result in cancer cells growth.
IGF-1 and others growth factors also have a stimulat-
ing effect on cancer cells and cause intracellular con-
version of estron to estradiol. Testosterone causes an
increase in the level of EGF (Endothelial Growth Fac-
tor) and provides a mitogenic stimulus for cancer cells. 
However, all the fore mentioned observations do not
allow for an explicit conclusion that PCOS as 
a disease entity predisposes towards greater occurrence
of cancer. This paper provides description of studies that
aimed at showing correlation between PCOS and cancer
risk and underlying theoretical assumptions.   
Infertility, obesity and hiperinsulinemia in
PCOS and their links with cancer 
PCOS is a disease entity which differs in its clinical
manifestation [1,2]. Not all the patients suffer from
obesity (only 40-50%) [3], infertility (but problems
with fertility affect 75% of women) [4] or hipertestos-
teronism related symptoms. On the other hand, all of
these problems may coexist in one patient.
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Abstract: Polycystic ovary syndrome (PCOS) affects approximately 5 to 10% of women of reproductive age. It is the most
common reason of anovulation in infertile women. PCOS is accompanied by such conditions as oligo- or anovulation,
hipertestosteronism, lower cell sensitivity to insulin, type II diabetes, hyperlipidemia and obesity. Each of the above-men-
tioned conditions is an approved risk factor proved to predispose towards cancer. However, PCOS is also a disease entity
which differs in its clinical manifestation. For example not all patients suffer from obesity or hipertestosteronism related
symptoms. From the analysis of literature it is possible to draw conclusions, that there is a possible correlation between
PCOS and endometrial cancer, which emerges from clinical trials or research focused on molecular changes in endometri-
um patients with PCOS. On the other hand, correlation between PCOS and breast or ovary cancer is not so strong, in spite
of single papers which are showing the link. The main problem in researching the correlation between PCOS and any can-
cer risk, is there is a very small group of women or the trial is imperfect (e.g. no control group). There is no meta-analysis
focused on this correlation in literature. The change of criteria of PCOS in the past is also a big problem, because there was
a number of definitions of PCOS, which results in inconsistent PCOS diagnoses over time.  In this paper we would like to
provide a description of studies that aimed at showing correlation between PCOS and cancer risk and underlying theoreti-
cal assumptions.
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Review article
As mentioned above infertility problems affect ca.
75% of PCOS patients. Many papers provide conclu-
sions on correlation between infertility and cancer. It
seems that it is infertility that most eminently predispos-
es towards cancer in PCOS women.  Correlation
between infertility and cancer was proved in epidemio-
logic research and single case reports. In 1983 Coulam et
al. [5] proved 3-times higher risk of endometrial cancer
in patients suffering from chronic anovulation. Another
research team [6] traced back cases of patients with
1964-1974 history of infertility treatment. In this
research the most frequent cause of infertility was of
hormonal nature, followed by other causes (male factor,
mechanical infertility). Researchers showed 4.8-fold risk
of endometrial cancer and 10.8-fold risk of cancer in
infertile patients with chronic anovulation. In the follow-
ing paper [7], risk of endometrial cancer was linked to
childlessness as researchers found out that there were
more nullipara in the group of patients with cancer, and
women who were infertility-treated (diagnosed with
infertility) displayed 7.6-fold risk of endometrial cancer.
From the above mentioned research, as well as other
papers [8] one can conclude that infertility increases risk
of endometrium cancer, especially if accompanied by
chronic anovulation. This coincidence takes place in
PCOS. 
These conclusions are not that explicit, when one
tries to link infertility to other types of cancer diagnosed
in women. Many papers aimed at linking breast cancer
to hormonal factors. In the case of infertile patients there
exist both papers which show higher incidence, as well
as reverse effect. Risk factors that lead to breast cancer
development are conditions connected with higher pro-
duction of endogen hormones, which is also the case in
PCOS. Ron et al. [6] and Brinton et al. [7] did not show
correlation between infertility and breast cancer. These
conclusions were confirmed in other research. [9,5].
However, one research [10] showed 1.8-fold risk in
infertile patients with chronic anovulation, and yet
another one showed 5.4-fold incidence of breast cancer
in pre-menopause women who were previously diag-
nosed with anovulation. Two other papers seem very
interesting with respect to PCOS patients. One of them
[11] showed that in breast cancer patients suffering from
ovulation problems the risk of breast cancer was 3.5-
times higher. If the same patients had signs of hyperan-
drogenism (persistent acne, excess of body hair), the risk
was 6.8 higher. At the time of diagnosis most of patients
in this research were in postmenopausal age (60%). The
second paper [5] showed that in patients with obesity,
hypertension and diabetes (conditions that frequently
coincide with PCOS) the risk of breast cancer is 
3-times higher. 
Contrary to the fore-mentioned papers there are also
papers on correlation between ovarian cancer and infer-
tility. Most research show correlation. One of basic fac-
tors of ovarian cancer is childlessness and anovulation
[12]. In a research by McGovan et al. [13] risk of ovari-
an cancer in nullipara was 2.45-times higher compared
to multipara and 1.27-times higher compared to unipara.
The analysis of 12 case control studies [14] showed 2.1-
fold risk in nullipara with infertility history. 
Obesity, which coincides with PCOS, is a risk factor
in all the above mentioned types of cancer. Meta-analy-
sis of studies into coincidence of ovarian cancer and
obesity showed that in 10 per 28 population-based stud-
ies correlation was statistically significant, and pooled
effect estimate for adult obesity was 1.3 (95% CI 1.1-
1.5)[15], which had previously been showed in one
smaller paper [16]. Recent epidemiologic studies have
shown a positive relationship between BMI and breast
cancer with a significant relative risk ranging from 1.26
to 2.52 [17].  
Theoretical premises for correlation of PCOS and
cancer are based on very specific observations. Unop-
posed stimulation of the endometrium in the setting of
chronic anovulation in women with PCOS is an
acknowledged factor leading to endometrial cancer
development [18]. Estrogens are also an acknowl-
edged factor of breast cancer, as they stimulate duct
breast tissue. They also stimulate – under laboratory
conditions – cancer cell growth [19]. In cell lines,
estrogens have been shown to have a variety of
actions, specifically to increase concentrations of
Transforming Growth Factor (TGF) and Insulin
Growth Factor 1 (IGF-1) [20]. In PCOS estrogen con-
centration may rise as a result of a number of mecha-
nisms. First and foremost, chronic anovulation does
not lead to higher concentration, but to chronic
endometrial stimulation with estrogens. Stimulation,
which is not antagonized by progesteron in the course
of disturbed cycle, may lead to persistent endometrial
proliferation. Estrogen concentration may rise in obese
patients. In PCOS patients the main source of estro-
gens are androgens, whose concentration also rises in
the course of PCOS. In the case of obese patients con-
centration of sex hormone-binding globulin (SHBG)
decreases, which leads to higher concentration of free
androgens, followed by their peripheral conversion to
estrogens. PCOS accompanying hyperinsulinemia also
leads to higher estrogen concentration by direct impact
of insulin on androgen production in ovaries. Andro-
gens may also individually stimulate endometrial
growth. Insulin receptors are present both in
endometrium of healthy patients, as well as in patients
with endometrial cancer, which may suggest the role
of hyperinsulinemia in genesis and progression of
endometrial cancer [21]. Hyperinsulinemia also causes
IGF-1 (Insulin Growth Factor-1) concentration to rise.
Its concentration rises as well as a result of estrogen
stimulation, by inhibited production of Insulin Growth
Factor Binding Protein I (IGFBP I) [22]. IGF-1 is
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growth factor which can stimulate tumor genesis and
tumor progression. In mice growth factors have malig-
nant transforming potential [23,24]. Growth factors
can be chemotactic to blood vessels [25,26]. Insulin
also causes higher concentration of another growth
factor, i.e. VEGF (Vascular Endothelial Growth Fac-
tor) [27]. IGF receptors were detected in breast cancer
cells, and its mitotic activity was greater than that of
estradiol [28]. Within the uterus gen activity for IGF is
stimulated by estrogens [29]. The actions of insulin on
the endometrium in vivo are difficult to distinguish
from the actions of androgens because hyperandro-
genism and hyperinsulinemia are positively correlated
in women with anovulation [30]. In obese women
there is also higher concentration of adipokines, pro-
teins synthesized in fat cells. Adipokines include i.a.:
leptin, TNF-α (Tumor Necrosis Factor α), interleukin-
6, hepatocyte growth factor, and heparin-binding epi-
dermal growth factor-like growth factor (HB-EGF).
Leptin, for example can be proliferative factor for
breast cancer cells in vitro [17]. 
Endometrial cancer 
From both clinical and experimental research one can
conclude that correlation between PCOS and endome-
trial cancer is the strongest. Endometrium of PCOS
patients is known to be more sensitive to steroid hor-
mones. Women with PCOS exhibit elevated endome-
trial androgen receptor expression compared to nor-
mal, fertile controls [31], and endometrium of PCOS
patients shows higher concentration of estrogen recep-
tors [32]. It was also proved that PCOS patients exhib-
it higher Cyr61 protein expression [33], protein which
is integrin-binding, angiogenic factor, that also pro-
motes cell migration and adhesion. This protein is also
an apoptosis regulator and is associated with tumorge-
nesis [34]. Higher Cyr61 expression was also present
in uterine myoma [35] and in endometriosis [36]. In
the case of breast cancer its elevated expression was
found both in tumor biopsy and in metastasis [37]. In
the course of PCOS endometrial homeostasis is dis-
turbed. Apart from a change in Cyr61 production, 
a number of other modifications are identified; 
a change in Ki-67 expression, lower p53 production,
higher cyclin D1 expression and higher bcl-2/bax ratio
[38,39]. Disturbed homeostasis may result from inten-
sified proliferation which may in turn lead to abnormal
cell division possibly followed by tumorgenesis. How-
ever, clinical studies do not provide straightforward
answer to the question about correlation between
PCOS and endometrial cancer. This correlation was
observed as early as 1949, 14 years after the first
description of the syndrome [40]. However, both this
and some other studies on this problem [41,42] did not
include study controls, which disqualifies explicit con-
clusions. Remaining studies [43-45] did not show cor-
relation between PCOS and endometrial cancer. In 
a number of studies PCOS patients were not identified
in the overall study group [46-48]. One study showed
that obesity caused risk to rise 3-fold in patients diag-
nosed with endometrial cancer compared to non-obese
patients, which may imply that infertility does not
have to be an independent risk factor of endometrial
cancer in PCOS women [49]. There was also an
attempt to conclude that PCOS may provide better
prognosis once endometrial cancer has been diagnosed
[50], as histopathological research of preparations
from PCOS patients showed well differentiated tumors
or moderately well differentiated. However, this study
was carried out on only 6 patients and did not include
study control, which precludes talk of correlation. 
Ovarian cancer
The most quoted paper showing correlation between
ovarian cancer and PCOS is by Schildkraut et al. [51]. It
showed 2.5-fold risk of ovarian cancer in PCOS women
and as high as 10.5-fold risk in patients who did not
receive OC. Data were analyzed from a population-
based, case-control study, the Cancer and Steroid Hor-
mone Study, i.e. a study that did not aim to evaluate
ovarian cancer in PCOS women. In the group of patients
diagnosed with ovarian cancer there were only 7 PCOS
women who accounted for 1.5% of the group, while in
the study control there were 24 cases of PSOC, i.e.
0.06% of the control. Conclusions on correlation
between ovarian cancer and PCOS seem inaccurate
based on such a small group of PCOS patients in
research groups. Most studies on correlation between
PCOS and ovarian cancer failed to show a link [52,46].
An interesting exception is a paper by Rossing et al. [53],
investigating connections among infertility, ovarian can-
cer and ovulation inducing drugs. Clomiphen treatment
caused 2.3-fold risk of ovarian cancer in these women.
These results were confirmed in other studies [54-56].
Breast cancer 
In the case of correlation between breast cancer and
PCOS proofs are also not convincing, and research
results even show reverse correlation [57,58]. The
basic problem underlying theses studies was the fact
that in the second study PCOS women accounted just
for 0.94% of the study control and for 0.49% of breast
cancer group, while in the first study for 1.35% of the
overall study group. Another drawback of these stud-
ies was that patients reported PCOS by themselves. It
seems one cannot talk of correlation between breast
cancer as PCOS, just as in the case of ovarian cancer. 
Problems with proper evaluation of correlation
between PCOS and respective factors are present in 
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a paper showing higher mortality of PCOS patients
from breast cancer compared to healthy population
[59]. This paper traces back medical records of
patients diagnosed with PCOS in their lifetime in order
to determine standardized mortality ratio (SMR). It
was proved that SMR for breast cancer was 1.48 in this
group, while mortality was not higher from circulation
diseases at the same time. However, as soon as 2 years
later the same study group released study results that
did not show correlation between deaths from breast
cancer and PCOS despite the same patient group. Dif-
ferent conclusions resulted from modified methodolo-
gy of the study [60]. 
Based on available literature one may draw a con-
clusion that correlation between adenocarcinoma of
endometrium and PCOS is likely to exist. This results
both from clinical trials and papers on changes of
endometrium in PCOS patients. However, despite sin-
gle papers that report on the link, correlation between
ovarian or breast cancer and PCOS is doubtful. 
Conclusions
Fundamental problem in estimating correlation between
PCOS and tumor formation exists primarily in a limited
number of reports on this problem. If research does exist,
there has been either too small patient group or it has not
been properly conducted from the very beginning (e.g. no
control group). This is why no meta-analysis was devel-
oped on this issue. Another problem in estimation of cor-
relation between PCOS and tumor formation is change-
ability of criteria for PCOS diagnosis. Changes have been
proposed three times since modern criteria for PCOS
diagnosis (NIH) were first determined in 1990 (Homburg
2002, ESHREVASRM-Rotterdam 2003, AES 2006).
This may affect the results of retrospective studies, which
are most commonly the case in investigating correlation
between PCOS and tumor formation. A case diagnosed as
PCOS does not have to be qualified as such based on
present-day criteria.  What seems indispensable for prop-
er evaluation of the issue is large randomized research
that will enable to draw final conclusions based on prop-
er theses and appropriate patient selection. 
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